Mouse mannose-binding lectin-A and ficolin-A inhibit lipopolysaccharide-mediated pro-inflammatory responses on mast cells

Ying Jie Ma1,3, Hee Jung Kang2, Ji Yeon Kim2, Peter Garred3, Myung-Shik Lee4 & Bok Luel Lee1,*

1The Global Research Laboratory of Insect Symbiosis, College of Pharmacy, Pusan National University, Busan 609-735, 2Department of Laboratory Medicine, Hallym University College of Medicine, Anyang 431-070, Korea, 3Laboratory of Molecular Medicine, Department of Clinical Immunology, Sect 7631, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, 4Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea

INTRODUCTION

Innate immunity provides the first line of host defence against the invasion of pathogenic microbes (1). Crucial host immune-surveillance cells, such as dendritic cells, macrophages, and mast cells, function as sentinels, by providing early warning signals, and by the activation of host defence responses against invading pathogenic bacteria (2, 3). These innate immune responses can be achieved by the direct recognition of bacteria through pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs) and complement receptors, which are activated in response to the recognition of pathogen-associated molecular patterns (PAMPs), such as bacterial lipopolysaccharide (LPS), lipoproteins, and fungal 1,3-β-D-glucan (4-7). Mast cells have been reported to produce different types of cytokines and chemokines, including pro-inflammatory and anti-inflammatory mediators, in response to different types of PAMPs stimuli. Therefore, they are thought to play a role in linking innate defenses to adaptive immune responses, and in orchestrating the overall host immune responses (5, 8).

Mannose-binding lectin (MBL) and ficolins are multifunctional soluble PRRs that are crucial in the initiation of lectin complement pathway upon binding to microbial PAMPs, leading to bacterial lysis and phagocytosis of opsonized microbes (9, 10). MBL and ficolins are oligomeric proteins assembled from subunits consisting of two distinct functional domains: the collagen-like domain, and the carbohydrate-recognition domain and fibrinogen-like domain, respectively, whereby cytokine production by LPS-mediated TLR4 in mBMMCs appears to be down-regulated, indicating that mouse MBL and ficolin may have an inhibitory function toward mouse TLR4-mediated excessive inflammation on the mast cells. [BMB Reports 2013; 46(7): 376-381]

*Corresponding author. Tel: +82-51-510-2809; Fax: +82-51-513-2801; E-mail: brlee@busan.ac.kr

Received 11 March 2013, Revised 12 March 2013, Accepted 12 March, 2013

Keywords: Ficolin, Innate immunity, Mannose-binding lectin, Mast cell, Toll-like receptor

ISSN: 1976-670X (electronic edition)
Copyright © 2013 by the The Korean Society for Biochemistry and Molecular Biology
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
cytes, neutrophils, and alveolar epithelial cells, and recently has been shown to be present in serum at low concentrations (15). In mice, two types of ficolins, ficolin-A and ficolin-B, have been identified. Ficolin-A is highly expressed in the liver and spleen, and is present in the serum, while ficolin-B is expressed in bone marrow and the spleen. Based on the structural and functional properties and phylogenetic analysis, ficolin-A resembles human ficolin-2, while ficolin-B is more homologous with human ficolin-1 (13).

MBL and ficolins have been reported to recognize a wide range of clinically important microbes, including bacteria, fungi, and viruses, and then induce specific innate immune responses (9, 10, 16, 17). It has been shown that MBL and ficolins bind to the LPS of bacteria, and then induce the activation of the TLR4 signaling pathway, leading to the mediation of inflammatory responses during infection (13, 18). Several reports have shown that molecules like MBL and the analogous lung surfactant proteins-A (SP-A) or SP-D regulate inflammatory cellular responses on various immune cells by different mechanisms upon stimulation with PAMPs (19-22). Since the molecular regulatory mechanisms between mast cells, host MBL, and ficolins during bacterial infection are largely unknown, in this study, we investigate the effect of mouse MBL-A and ficolin-A on LPS-induced inflammatory cytokine production using mouse bone marrow stem cell-derived mast cells (mBMMCs).

RESULTS

Bacterial LPS induced IL-6 production on mouse mast cells via TLR4-dependent manner

To examine the biological functions of mouse TLR2 and TLR4 during mast cell-mediated cytokine production in response to PAMP stimuli, we estimated the amounts of mouse IL-6 (mIL-6) production on mBMMCs prepared from Toll-like receptor 2 (TLR2)-deficient mice (Tlr2-/-), TLR4-deficient mice (Tlr4-/-), and their wild type (Tlr2+/+ and Tlr4+/+). When these mast cells were stimulated with N-palmitoyl-S-dipalmitoylglyceryl-Cys-Scr(Lys)4 (Pam3CSK4) and LPS, which are known to be typical ligand molecules of TLR2 and TLR4, respectively, Pam3CSK4-treated mast cells produced mIL-6 vigorously, but the Tlr2-/- mast cells did not, while LPS did not show any significant difference (Fig. 1A). However, as expected, when we stimulated Tlr4-/- derived mast cells or Tlr4+- derived mast cells with LPS, Tlr4-/- derived mast cells produced mIL-6, but the Tlr4+- mast cells did not (Fig. 1B). These results clearly suggest that mouse mast cells produce IL-6 in response to Pam3CSK4 and LPS distinctly in a TLR2-dependent and TLR4-dependent manner, respectively.

Mouse MBL-A and ficolin-A attenuate LPS-induced inflammatory cytokine production on mBMMCs

To determine whether MBL and ficolins can modulate LPS-mediated inflammatory cytokine production in mast cells, mBMMCs were stimulated with LPS in the presence of mouse MBL-A or mouse ficolin-A. When the amounts of mIL-6 and mTNF-α were determined by ELISA, both proteins suppressed LPS-mediated mIL-6 and mTNF-α production on mBMMCs in a dose-dependent manner (Fig. 2A and 2B). Nevertheless, Pam3CSK4-mediated mIL-6 production was not affected by addition of mouse MBL-A or ficolin-A (data not shown). These results indicate that mouse MBL-A and ficolin-A specifically inhibit LPS-mediated inflammatory cytokine production in mouse mast cells.

Mouse MBL-A and ficolin-A bind to LPS, not to extracellular domain of TLR4 in mast cells

To examine the possibility of whether mouse MBL-A and ficolin-A bind to LPS via the CRD domain of MBL-A and the FBG domain of ficolin-A, LPS was pre-incubated with mouse MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins. In accordance with previous results, pre-incubation of LPS with MBL-A or ficolin-A prior to the stimulation of mast cells. As a control group, we prepared samples of directly incubated LPS with prepared mast cells before adding proteins.
Function of mouse MBL-A and ficolin-A
Ying Jie Ma, et al.

**Fig. 2.** Mouse MBL-A and ficolin-A suppress LPS-mediated IL-6 and TNF-α production on mBMMCs. mBMMCs were stimulated with LPS (200 ng/ml, smooth type from *E. coli* serotype O4), which was pre-incubated with mouse MBL-A or ficolin-A. As a negative control, buffer alone was used instead of LPS. mIL-6 (A) and mTNF-α (B) levels in the supernatant were determined by ELISA. Data are represented as means ± S.D. from triplicate experiments. Results are representative of at least three independent experiments that yield similar results.

**Fig. 3.** Mouse MBL-A and ficolin-A attenuate LPS-mediated IL-6 production through direct binding to LPS, but not through TLR4 on mBMMCs. (A) LPS (200 ng/ml, smooth type from *E. coli* serotype O4) was pre-incubated with mouse MBL-A (1,000 ng/ml) or ficolin-A (1,000 ng/ml) prior to stimulation of mBMMCs. (B) Simultaneously, mBMMCs were pre-incubated with mouse MBL-A or ficolin-A before stimulation with LPS. mIL-6 levels in the supernatants were determined by ELISA. Data are represented as means ± S.D. from triplicate experiments. Results are representative of three independent experiments that yield similar results. Asterisk indicates the statistical significance versus controls: *P* < 0.01.

whereas the pre-treatment of mast cells with the host lectin proteins did not clearly affect mIL-6 production (Fig. 3B), indicating that mouse MBL-A and ficolin-A attenuate LPS-mediated cytokine production through direct interaction with LPS, but not with TLR4 extracellular domain on mouse mast cells.

Mannose and GlcNAc restored inhibitory effect of mouse MBL-A and ficolin-A toward LPS-mediated inflammatory cytokine production in mast cells
To further validate the obtained results, LPS was pre-incubated with mouse MBL-A or ficolin-A in the presence of mannose or GlcNAc prior to stimulation of mast cells. By the addition of mannose or GlcNAc to the reaction mixture, LPS-mediated mIL-6 production was significantly reduced on mBMMCs (Fig. 4). However, mannose or GlcNAc alone did not show any influence on mast cell activation or on LPS-mediated cytokine production on mast cells (data not shown). These results strongly suggest that the binding of mouse MBL-A and ficolin-A to LPS occurs via the CRD domain of MBL-A and the FBG domain of mouse ficolin-A, respectively, and further supported our previous results that mouse MBL-A and ficolin-A inhibit LPS-mediated cytokine production on mast cells through binding to LPS.

**DISCUSSION**

In this study, we have demonstrated that LPS-mediated mIL-6 and mTNF-α production on mBMMCs is attenuated by the addi-
tion of mouse MBL-A or ficolin-A. Several reports have shown a regulatory role of host lectins, such as MBL, SP-A, and SP-D, in response to invading pathogens (19-22). MBL has been reported to inhibit bacterial peptidoglycan (PGN)-mediated inflammatory cytokine secretion on phorbol myristate acetate-stimulated U937 cells, and also to promote chemokine production, suggesting the importance of MBL binding to the GlcNAc residues of PGN (19). In contrast, SP-A inhibits PGN-mediated TNF-α secretion in U937 cells and alveolar macrophages by direct interaction with the extracellular domain of TLR2, rather than binding to PGN (21). Gardai et al. have proposed dual functions of lung collectins in macrophage-mediated pro-inflammatory immune responses, because the interaction between the collagenous tail of SP-A or SP-D and calreticulin/CD91 enhances immune responses, to the extracellular domain of TLR2, rather than binding to PGN (21). Gardai et al. have proposed dual functions of lung collectins in macrophage-mediated pro-inflammatory immune responses, because the interaction between the collagenous tail of SP-A or SP-D and calreticulin/CD91 enhances immune responses, to the extracellular domain of TLR2, rather than binding to PGN (21).

In 1996, two reports described that mast cell-deficient mice show increased mortality after E. coli infection (2, 3), suggesting a crucial role of mast cells in bacterial infection, and a minor contribution of complement activation by MBL. However, clinical studies also revealed that MBL-deficient individuals are more likely to develop systemic inflammatory response syndrome (SIRS) and to progress to septic shock (28), suggesting MBL may also be involved in the modulation of inflammatory responses. How MBL exerts a modulatory function in this disease remains unclear, suggesting that human MBL may have multiple mechanisms in vivo.

In this study, we have shown that murine MBL-A and ficolin-A have an anti-inflammatory function by interfering with the interaction between LPS and TLR4 on mast cells. These findings provide insight into the pathogenesis of the diseases, and also into how collagenous domain-containing host defense proteins respond to bacterial infection at a mast cell-distributed host-environment interface.

MATERIALS AND METHODS

Mice
C57BL/6 mice were purchased from Hyochang Science (Daeu, Korea). TLR4-deficient mice (Tlr4−/−, C3H/HeN background) and its wild type (strain C3H/HeN) were purchased from Jackson Laboratory (Bar Harbor, Maine). TLR2-deficient mice (Tlr2−/−) and the corresponding wild type mice were kindly provided by Professor Shizuo Akira (Osaka University, Osaka, Japan). All mice were maintained in specific pathogen-free conditions at the Samsung Biomedical Research Center Facility. All animal experiments in this study were done in accordance with the institutional guidelines of the Samsung Medical Center.

Cell culture
Mouse bone marrow stem cell-derived mast cells (mBMMCs) were prepared and cultured as previously described (29, 30). Briefly, mouse bone marrow stem cells were isolated from the femur and tibia of 6~8-week-old mice, and cultured to a final density of 1 × 10^8 cells/ml in Iscove's modified Dulbecco's medium (IMDM) (Gibco) supplemented with L-glutamine (2 mM, Sigma), heat inactivated fetal calf serum (10%, Gibco), penicillin (100 IU/ml, Sigma), streptomycin (100 μg/ml, Sigma), murine stem cell factor (SCF) (30 ng/ml, Peprotech), and IL-3 (30 ng/ml, Peprotech) at 37°C, in 5% (v/v) CO2 air with 95% humidity. The cultural medium was changed every 5-7 days. Non-adherent cells were collected and transferred to fresh medium, which were maintained for approximately 8 weeks. The homogeneity of mast cells was determined by staining with toluidine blue and FACS analysis. Cells cultured
for 7-9 weeks were used in the experiments.

**Cytokine assay**

Mouse MBL-A and ficolin-A were purified from mouse serum (Aleken Biologicals, Nash, TX) using Staphylococcus aureus PGN-coupled Sepharose 4B, as previously described (31). Smooth-type LPS from *E. coli* serotype O4 were kindly provided by the Borstel Research Center (Germany). Mast cells were harvested by centrifugation at 1,000 rpm for 5 min and suspended with basal medium in the absence of SCF and IL-3 for overnight starvation. For the induction of cytokines, mast cells were suspended with fresh basal medium and seeded into the wells of 96-well culture plates (SPL, Korea) (0.25 × 10⁶ cells/150 μl of basal medium) and stimulated in triplicate with LPS (200 ng/ml) for 6 hr at 37°C, in 5% (v/v) CO₂ air with 95% humidity. After stimulation, the supernatant from each well was collected by centrifugation at 1,000 rpm for 7 min and used for a subsequent cytokine assay. To measure the levels of mIL-6 and mTNF-α in each supernatant, mIL-6 and mTNF-α ELISA were performed according to the manufacturer’s instructions (Duoset ELISA, R&D).

In some experiments, mast cells from Tlr4⁻/⁻, Tlr2⁻/⁻, and their wild type were used to determine the effect of TLR4 and TLR2 on mast cell-mediated IL-6 production in response to LPS and N-palmitoyl-S-dipalmitoylglyceryl Cys-Scr-(Lys)⁴ (Pam3CSK tetra-peptide, (EMC Microcollections GmbH), respectively. After the stimulation of these cells with LPS (200 ng/ml) or Pam3CSK4 (2.5 μg/ml), IL-6 levels in the supernatant were analyzed as described above.

To determine the effect of mouse MBL-A or ficolin-A on LPS-induced cytokine production in mast cells, LPS (200 ng/ml) was pre-incubated with or without each protein (10, 100, 1,000 μg/ml) for 80 min at room temperature prior to stimulation. To understand the involvement of TLR4 as well as LPS and Pam3CSK4 in the case described above, each protein (1,000 ng/ml) was pre-incubated with mast cells for 3 hr before stimulation with LPS (200 ng/ml), which was simultaneously compared with the previous setup, with pre-incubation of LPS (200 ng/ml) with each protein (1,000 ng/ml) for 80 min before stimulation. IL-6 levels in the supernatant were analyzed as described above.

In some experiments, to determine the effect of mannose or GlcNAc on the LPS-mediated immune responses described above, both proteins were pre-treated with LPS in the presence or absence of mannose (0.1M) or GlcNAc (0.1M) to inhibit their binding to LPS before the stimulation of mast cells. As a control, mast cells were only incubated with mannose or GlcNAc in the presence or absence of LPS. IL-6 levels in the supernatant were analyzed as described above.

**Statistical analysis**

Data are represented as the mean ±S.D. of at least three independent experiments. Statistical analysis was performed using Student’s t test. P < 0.01 was considered statistically significant between two sample means.

**Acknowledgements**

The authors are grateful to Professor Misao Matsushita (Tokai University, Kanagawa, Japan) for providing rat monoclonal antibodies against mouse MBL-A and ficolin-A, Professor Shizuo Akira (Osaka University, Osaka, Japan) for providing Tlr2⁻/⁻ mice and corresponding wild type mice, and Professor Helmut Brade (Borstel Research Center, Borstel, Germany) for providing purified LPSs. This work was supported for two years by a Pusan National University Research Grant.

**REFERENCES**

1. Medzhitov, R. (2007) Recognition of microorganisms and activation of the immune response. *Nature* **449**, 819-826.

2. Malaviya, R., Ikeda, T., Ross, E. and Abraham, S. N. (1996) Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. *Nature* **381**, 77-80.

3. Echtenacher, B., Mannel, D. N. and Hultner, L. (1996) Critical protective role of mast cells in a model of acute septic peritonitis. *Nature* **381**, 75-77.

4. Trinchieri, G. and Sher, A. (2007) Cooperation of Toll-like receptor signals in innate immune defence. *Nat. Rev. Immunol.* **7**, 179-190.

5. Supapajatura, V., Ushio, H., Nakao, A., Akira, S., Okumura, K., Ra, C. and Ogawa, H. (2002) Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. *J. Clin. Invest.* **109**, 1351-1359.

6. Medzhitov, R. and Janeway, C. A. Jr. (2002) Decoding the patterns of self and nonself by the innate immune system. *Science* **296**, 298-300.

7. Janeway, C. A. Jr. and Medzhitov, R. (2002) Innate immune recognition. *Annu. Rev. Immunol.* **20**, 197-216.

8. Frosi, B., De Carli, M. and Pucillo, C. (2004) The mast cell: an antenna of the microenvironment that directs the immune response. *J. Leukoc. Biol.* **75**, 579-585.

9. Endo, Y., Matsushita, M. and Fujita, T. (2007) Role of ficolin in innate immunity and its molecular basis. *Immunobiology* **212**, 371-379.

10. Takahashi, K., Ip, W. E., Michelow, I. C. and Ezekowitz, R. A. (2006) The mannose-binding lectin: a prototypic pattern recognition molecule. *Curr. Opin. Immunol.* **18**, 16-23.

11. Garred, P., Honore, C., Ma, Y. J., Munthe-Fog, L. and Hummelshoj, T. (2009) MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. *Mol. Immunol.* **46**, 2737-2744.

12. Thiel, S., Vorup-Jensen, T., Stover, C. M., Schwaeble, W., Laursen, S. B., Poulsen, K., Willis, A. C., Eggleton, P., Hansen, S., Holmskov, U., Reid, K. B. and Jensenius, J. C. (1997) A second serine protease associated with mannann-binding lectin that activates complement. *Nature* **386**, 506-510.

13. Fujita, T., Matsushita, M. and Endo, Y. (2004) The lectin-complement pathway-s role in innate immunity and evolution. *Immunol. Rev.* **198**, 185-202.
14. Sallenbach, S., Thiel, S., Aebi, C., Otth, M., Bigler, S., Jensenius, J. C., Schlapbach, L. J. and Ammann, R. A. (2011) Serum concentrations of lectin-pathway components in healthy neonates, children and adults: mannan-binding lectin (MBL), M-, L- and H-ficolin, and MBL-associated serine protease-2 (MASP-2). Pediatr. Allergy Immunol. 22, 424-430.

15. Honore, C., Rorvig, S., Munthe-Fog, L., Hummelshoj, T., Madsen, H. O., Borregaard, N. and Garred, P. (2008) The innate pattern recognition molecule Ficolin-1 is secreted by monocytes/macrophages and is circulating in human plasma. Mol. Immunol. 45, 2782-2789.

16. Ma, Y. J., Doni, A., Skjoedt, M. O., Honore, C., Arendrup, M., Mantovani, A. and Garred, P. (2011) Heterocomplexes of mannan-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system. J. Biol. Chem. 286, 3405-3417.

17. Ma, Y. J., Doni, A., Hummelshoj, T., Honore, C., Bastone, A., Mantovani, A., Thielen, N. M. and Garred, P. (2009) Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition. J. Biol. Chem. 284, 28263-28275.

18. Neth, O., Jack, D. L., Dedds, A. W., Holzel, H., Klein, N. J. and Turner, M. W. (2000) Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect. Immun. 68, 688-693.

19. Nadesalingam, J., Dedds, A. W., Reid, K. B. and Palaniyar, N. (2005) Mannose-binding lectin recognizes peptidoglycan via the N-acetyl glucosamine moiety, and inhibits ligand-induced proinflammatory effect and promotes chemokine production by macrophages. J. Immunol. 175, 1785-1794.

20. Kang, H. J., Lee, S. M., Lee, H. H., Kim, J. Y., Lee, B. C., Yum, J. S., Moon, H. M. and Lee, B. L. (2007) Mannose-binding lectin recognizes peptidoglycan without the aid of its associated serine proteases alters lipopolysaccharide-mediated cytokine/chemokine secretion from human endothelial cells. Immunology 122, 335-342.

21. Murakami, S., Iwaki, D., Mitsuzawa, H., Sano, H., Takahashi, H., Voelker, D. R., Akino, T. and Kuroki, Y. (2002) Surfactant protein A inhibits peptidoglycan-induced tumor necrosis factor-alpha secretion in U937 cells and alveolar macrophages by direct interaction with toll-like receptor 2. J. Biol. Chem. 277, 6830-6837.

22. Yamada, C., Sano, H., Shimizu, T., Mitsuzawa, H., Nishitani, C., Himi, T. and Kuroki, Y. (2006) Surfactant protein A directly interacts with TLR4 and MD-2 and regulates inflammatory cellular response. Importance of supramolecular oligomerization. J. Biol. Chem. 281, 21771-21780.

23. Gardai, S. J., Xiao, Y. Q., Dickinson, M., Nick, J. A., Voelker, D. R., Greene, K. E. and Henson, P. M. (2003) By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 115, 13-23.

24. Sano, H., Chiba, H., Iwaki, D., Sohma, H., Voelker, D. R. and Kuroki, Y. (2000) Surfactant proteins A and D bind CD14 by different mechanisms. J. Biol. Chem. 275, 22442-22451.

25. Chiba, H., Sano, H., Iwaki, D., Murakami, S., Mitsuzawa, H., Takahashi, T., Konishi, M., Takahashi, H. and Kuroki, Y. (2001) Rat mannose-binding protein a binds CD14. Infect. Immun. 69, 1587-1592.

26. Varadaradjalou, S., Feger, F., Thieblemont, N., Hamouda, N. B., Pleau, J. M., Dy, M. and Arrock, M. (2003) Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur. J. Immunol. 33, 899-906.

27. McCurdy, J. D., Lin, T. J. and Marshall, J. S. (2001) Toll-like receptor 4-mediated activation of murine mast cells. J. Leukoc. Biol. 70, 977-984.

28. Fidler, K. J., Wilson, P., Davies, J. C., Turner, M. W., Peters, M. J. and Klein, N. J. (2004) Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin. Intensive Care Medicine 30, 1438-1445.

29. Huber, M., Helgason, C. D., Damen, J. E., Liu, L., Humphries, R. K. and Krystal, G. (1998) The src homol-2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. Proc. Natl. Acad. Sci. U.S.A. 95, 11330-11335.

30. Ma, Y. J., Kim, C. H., Ryu, K. H., Kim, M. S., So, Y. I., Lee, K. J., Garred. P. and Lee, B. L. (2011) Adenosine derived from Staphylococcus aureus-engulfed macrophages functions as a potent stimulant for the induction of inflammatory cytokines in mast cells. BMB Rep. 44, 335-340.

31. Ma, Y. G., Cho, M. Y., Zhao, M., Park, J. W., Matsushita, M., Fujita, T. and Lee, B. L. (2004) Human mannose-binding lectin and L-ficolin function as specific pattern recognition proteins in the lectin activation pathway of complement. J. Biol. Chem. 279, 25307-25312.